Press Releases

INOVIO’s Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies

Posted on May 12, 2021

INOVIO Reports First Quarter 2021 Financial Results

Posted on May 10, 2021

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine

Posted on May 10, 2021

INOVIO to Present at Upcoming Investor Conferences in May

Posted on May 4, 2021

INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021

Posted on April 27, 2021

INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800

Posted on April 23, 2021

INOVIO’s COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern

Posted on April 15, 2021

INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel

Posted on March 15, 2021

INOVIO to Present at Upcoming Investor Conferences in March

Posted on March 4, 2021

INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results

Posted on March 1, 2021

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.